⌘K
Loading ticker…
As of 2026-08-24, Colgate-Palmolive Company (CL) has a 3-month relative strength percentile of 53 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 50. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 2.3%, relative volume 1.02×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
CL is in a stage 2 uptrend, week 1. Currently in a 122-day base; basing ADR 2.1% (broad 1.8%). VCP detected: inconclusive. RS line below base-start high. Distance from 50d / 200d: 0.8% / 6.2%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Positive EPS uses YoY change.
CL appears in 1 ETF as of Jun 2026: PY at 0.51% weight, $1M notional.
Held by 318 ETFs · $11.9B across latest filings · largest weight 4.38% (XLP).
Top 1 by value, from SEC N-PORT-P filings dated Jun 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| PY | 0.51% | $1M | new |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Attention is elevated versus its own recent norm without the relative strength to match — the loud-but-lagging pattern. Worth a skeptical eye; not a short signal.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY diluted average shares. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Related searches
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CL Jan avg: 2.46% median: 0.50% win: 50% σ: 9.34% n: 4 2022-04-12 → 2026-07-31 | CL Feb avg: 4.02% median: 3.96% win: 75% σ: 4.78% n: 4 2022-04-12 → 2026-07-31 | CL Mar avg: -1.16% median: 2.65% win: 75% σ: 8.61% n: 4 2022-04-12 → 2026-07-31 | CL Apr avg: 0.52% median: 0.15% win: 60% σ: 3.92% n: 5 2022-04-12 → 2026-07-31 | CL May avg: 0.60% median: 1.13% win: 80% σ: 4.55% n: 5 2022-04-12 → 2026-07-31 | CL Jun avg: 1.84% median: 1.72% win: 80% σ: 2.54% n: 5 2022-04-12 → 2026-07-31 | CL Jul avg: -1.74% median: -1.01% win: 20% σ: 3.68% n: 5 2022-04-12 → 2026-07-31 | CL Aug avg: 0.83% median: -0.21% win: 50% σ: 4.67% n: 4 2022-04-12 → 2026-07-31 (current) | CL Sep avg: -5.21% median: -4.06% win: 0% σ: 3.46% n: 4 2022-04-12 → 2026-07-31 | CL Oct avg: -0.65% median: 0.75% win: 50% σ: 7.39% n: 4 2022-04-12 → 2026-07-31 | CL Nov avg: 4.31% median: 4.60% win: 100% σ: 0.84% n: 4 2022-04-12 → 2026-07-31 | CL Dec avg: -1.19% median: -0.26% win: 50% σ: 3.49% n: 4 2022-04-12 → 2026-07-31 |